Evidence map›Paper›PMID 40791536›Full record

ArticlebioRxiv : the preprint server for biology2025

Increased vaccine efficacy against tuberculosis with a recombinant BCG overexpressing the STING agonist cyclic di-AMP.

Dhiraj K Singh, Peter Um, Garima Arora, Xavier Alvarez, Vinay Shivanna, Edward Dick, Smriti Mehra, William R Bishai

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dhiraj K SinghSouthwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, USA.
Peter UmJohns Hopkins School of Medicine, Center for TB Research, Baltimore, MD, USA.
Garima AroraSouthwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, USA.
Xavier AlvarezSouthwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, USA.
Vinay ShivannaSouthwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, USA.
Edward DickSouthwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, USA.
Smriti MehraSouthwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, USA.
William R BishaiJohns Hopkins School of Medicine, Center for TB Research, Baltimore, MD, USA.

Funding

The Southwest National Primate Research Center Supplement- Infrastructure improvements of ABSL2 holding areasP51OD011133 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Larry S. Schlesinger · 2012 to 2026
$129.7M
Viral Testing CoreU42OD010442 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Deepak Kaushal · 2012 to 2026
$35.6M
A STINGing vaccine for TBR01AI155346 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BISHAI, WILLIAM RAMSES, MEHRA, SMRITI · 2020 to 2024
$4.9M
Significant upgrade and expansion of the Southwest National Primate Research Center Pathology UnitS10OD028732 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI KAUSHAL, DEEPAK · 2020 to 2020
$489k
BD FACSymphonyS10OD028653 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI TURNER, JOANNE · 2020 to 2020
$463k
Dual Beckman Coulter DxH 690T and Beckman Coulter DxH 560 ALS10OD032443 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI TURNER, JOANNE · 2022 to 2022
$86k
NIAID NIH HHS R01 AI155346NIH HHS P51 OD011133NIH HHS S10 OD028653NIH HHS S10 OD028732NIH HHS S10 OD032443NIH HHS U42 OD010442
6 · The paper itself

Abstract

Tuberculosis (TB) remains the leading cause of death due to infection globally. Bacillus Calmette Guérin (BCG), a live attenuated bacterial strain, is the only available TB vaccine, but it has poor efficacy in preventing pulmonary TB in adults. There are advantages associated with the BCG platform however, including a remarkable safely profile, billions of administered doses and a public health ecosystem associated with its production, administration and care. A recombinant/modified BCG (rBCG/modBCG) anti-TB vaccine candidate would be able to leverage these advantages while improving on efficacy. BCG-STING is a recombinant BCG strain which overexpresses the mycobacterial diadenylate cyclase

Identifiers

PMID40791536
PMCPMC12338612

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.